J. Goldman & Co’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

J. Goldman & Co’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-20,301	Closed	-$2.18M	–	530
2023 Q1	$2.18M	Buy	+20,301	New	+$2.34M	0.09%	201
2022 Q4	–	Sell	-19,190	Closed	-$1.13M	–	528
2022 Q3	$1.13M	Sell	19,190 -20,028	-51%	-$916K	0.05%	247
2022 Q2	$1.11M	Buy	+39,218	New	+$1.14M	0.05%	245

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

J. Goldman & Co's RXDX Position: Q2 2023 in Review

J. Goldman & Co sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 20,301 shares — an estimated $2.18M sold.

J. Goldman & Co first reported a position in RXDX in Q2 2022 and held it in 3 quarters. The position peaked at $2.18M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

J. Goldman & Co reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
J. Goldman & Co sold 20,301 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $2.18M.
J. Goldman & Co first reported a position in Prometheus Biosciences, Inc. Common Stock in Q2 2022 and held it in 3 quarters.
J. Goldman & Co's Prometheus Biosciences, Inc. Common Stock position peaked at $2.18M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on J. Goldman & Co's 13F filing for Q2 2023, filed 14 Aug 2023.